Table 3.
Secondary efficacy outcomes
|
Baseline (post-erenumab) (N = 39) |
3rd month (N = 39) |
p value |
6th month (N = 21) |
p value |
Last treatment (N = 16) |
p value | |
|---|---|---|---|---|---|---|---|
| Total monthly headache days, median (IQR) | 30.0 (17.1–30.0) |
25.0 (12.9–30.0)a (2 md) |
0.001 | 17.1 (6.4–23.6) | 0.003 | 8.6 (4.3–17.1) | 0.001 |
| Monthly migraine days, median (IQR) | 21.4 (10.7–30.0) | 15.0 (8.6–30.0) | 0.007 | 8.6 (5.4–19.3) | 0.007 | 8.6 (3.8–13.9) | 0.001 |
| Crystal clear days, median (IQR) | 0.0 (0.0–10.7) |
1.0 (0.0–15.0)a (1 md) |
0.006 | 5.4 (0.0–20.4) | 0.023 | 7.5 (0.0–22.8) | 0.026 |
| Monthly painkillers intake, median (IQR) |
8.6 (5.4–19.3)a (2 md) |
0.0 (0.0–7.5)a (1 md) |
≤ 0.001 | 9.6 (5.4–13.9) | 0.201 |
5.4 (3.6–9.6)a (2 md) |
0.033 |
| HIT-6 score, median (IQR) |
66.0 (63.5–70.0)a (5 md) |
68.5 (65.0–70.0)a (15 md) |
- |
66.0 (64.0–71.0)a (12 md) |
- |
62.0 (50.0–66.0)a (3 md) |
- |
IQR interquartile range, HIT-6 Headache Impact Test-6, N number
amd missing data